You are here

Metalloproteinase Inhibitor For Pain and Morphine Tolerance Due To Thermal Injury

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43GM109469-01
Agency Tracking Number: R43GM109469
Amount: $261,982.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NIGMS
Solicitation Number: PA13-088
Timeline
Solicitation Year: 2014
Award Year: 2014
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
225 MYSTIC VALLEY PKWY
WINCHESTER, MA 01890-3130
United States
DUNS: 830934324
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 IRVING SUCHOLEIKI
 (617) 759-6590
 irvs@att.net
Business Contact
 IRVING SUCHOLEIKI
Phone: (617) 759-6590
Email: irvs@att.net
Research Institution
 Stub
Abstract

DESCRIPTION (provided by applicant): Aquilus Pharmaceuticals, Inc. proposes to evaluate the effects of a proprietary matrix metalloproteinase (MMP) inhibitor, AQU-010, for blocking neuropathic pain and morphine tolerance in a thermal injury (TI) rat model.The goals for Phase I are to scale-up the synthesis of AQU-010, determine its oral pharmacokinetics (PK) and target tissue penetration and then determine its efficacy in the TI-rat model of mechanical and thermal allodynia. A follow-up biomarker and gelatin zymography analysis will be performed to determine if any behavior changes observed from the animal model correspond to changes in metalloproteinase and/or cytokine levels. The ultimate goal of the proposed work is to evaluate whether a matrix metalloproteinase inhibitor can be used to treat pain and/or morphine tolerance in patients suffering from burn injuries without producing euphoria and addiction. PUBLIC HEALTH RELEVANCE PUBLIC HEALTH RELEVANCE: An estimated 1.25 million individuals

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government